PE14199A1 - Agonistas de 5-ht1f - Google Patents

Agonistas de 5-ht1f

Info

Publication number
PE14199A1
PE14199A1 PE1997001023A PE00102397A PE14199A1 PE 14199 A1 PE14199 A1 PE 14199A1 PE 1997001023 A PE1997001023 A PE 1997001023A PE 00102397 A PE00102397 A PE 00102397A PE 14199 A1 PE14199 A1 PE 14199A1
Authority
PE
Peru
Prior art keywords
ht1f
formula
agonists
compounds
ht1f agonists
Prior art date
Application number
PE1997001023A
Other languages
English (en)
Inventor
Sandra Ann Filla
John Mehnert Schaus
Lee Alan Phebus
Kirk Willis Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE14199A1 publication Critical patent/PE14199A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: A-B ES C=CH o CH-CH2; "X" ES NR1SO2R2, NHC(Q)NR3R4, NHCOOR5, NR1COR6; "Q" ES O o S; R ES H, ALQUILO C1-C6, BENCILO o FENILETILO; R1 ES H o ALQUILO C1-C4; R2 ES ALQUILO C1-C4 o FENILO OPCIONALMENTE SUSTITUIDO; R3 Y R4 SON H, ALQUILO C1-C6, ALQUENILO C3-C6, CICLOALQUILO C3-C8, FENILO, HETEROARILO, ENTRE OTROS, o R3 Y R4 JUNTO CON EL NITROGENO AL CUAL ESTAN UNIDOS FORMAN UN ANILO DE PIRROLIDINA, PIPERIDINA, PIPERAZINA, MORFOLINA o TIOMORFOLINA; R5 ES ALQUILO C1-C6, ALQUENILO C3-C6, FENILO OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-C8, ENTRE OTROS; R6 ES ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO, ALQUENILO C2-C10, ALQUINILO C2-C10, CICLOALQUILO C3-C8, FENILO OPCIONALMENTE SUSTITUIDO, NAFTILO, FENIL(ALQUILENO C1-C4) OPCIONALMENTE SUSTITUIDO, ENTRE OTROS. UN COMPUESTO (I) PREFERIDO ES: 5-(N-[PROPIONIL]AMINO)-3-(1-METILPIPERIDIN-4-IL)PIRROLO[3,2-b]PIRIDINA. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS SELECTIVOS DEL RECEPTOR DE SEROTONINA (5-HT) 1F, QUE EVITAN LOS EFECTOS SECUNDARIOS DE VASOCONSTRICCION ASOCIADOS A VARIOS SUBTIPOS DE RECEPTORES DE SEROTONINA, SIENDO UTILES EN EL TRATAMIENTO DE LA MIGRANA
PE1997001023A 1996-11-15 1997-11-13 Agonistas de 5-ht1f PE14199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3095096P 1996-11-15 1996-11-15

Publications (1)

Publication Number Publication Date
PE14199A1 true PE14199A1 (es) 1999-02-12

Family

ID=21856862

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001023A PE14199A1 (es) 1996-11-15 1997-11-13 Agonistas de 5-ht1f

Country Status (17)

Country Link
US (3) US5817671A (es)
EP (1) EP0842934B1 (es)
JP (1) JP2001503774A (es)
AT (1) ATE253063T1 (es)
AU (1) AU5435298A (es)
CA (1) CA2271272A1 (es)
CO (1) CO4910133A1 (es)
DE (1) DE69725825T2 (es)
DK (1) DK0842934T3 (es)
ES (1) ES2210463T3 (es)
ID (1) ID18883A (es)
IL (1) IL129592A0 (es)
NO (1) NO991974D0 (es)
PE (1) PE14199A1 (es)
PT (1) PT842934E (es)
WO (1) WO1998020875A1 (es)
ZA (1) ZA979961B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905084A (en) * 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
ZA989389B (en) * 1997-11-14 2000-04-14 Lilly Co Eli Pyrrolo [3,2-b] pyridine processes and intermediates.
US6133290A (en) * 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
WO2000034266A1 (en) * 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
ES2201899B1 (es) * 2002-04-01 2005-06-01 Almirall Prodesfarma, S.A. Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
NZ547327A (en) * 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
ES2291978T3 (es) 2003-12-17 2008-03-01 Eli Lilly And Company Compuestos de (4-aminociclohexen-1-il)fenilo y (4-aminociclohexen-1-il)piridinilo sustituidos como agonistas de 5-ht1f.
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006032A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
RU2486181C2 (ru) 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
EP2173723B3 (en) * 2007-07-05 2014-11-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
ES2422733T3 (es) * 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
NZ596161A (en) * 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック, インコーポレイテッド Akt及びmek阻害剤化合物の組み合わせ、及び使用方法
BG111544A (bg) 2013-07-29 2015-01-30 Николай Цветков Субституирани бензамидни производни като in vitro mao-b инхибитори
DK3027603T3 (en) * 2013-08-02 2018-09-17 Pfizer HETEROBICYCLOARYL-RORC2 INHIBITORS AND METHODS FOR USING IT
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
PL3416964T3 (pl) * 2016-02-19 2021-10-18 Phoenix Molecular Designs Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
AU2019323450A1 (en) 2018-08-24 2021-02-11 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3080374A (en) * 1962-02-08 1963-03-05 Abbott Lab 2-guanidino-3-nitropyridine and derivatives thereof
WO1990007926A1 (en) * 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CN1184425A (zh) * 1995-03-20 1998-06-10 伊莱利利公司 5-取代-3-(1,2,3,6-四氢吡啶-4-基)-和3-(哌啶-4-基)-1h-吲哚:新型5-ht1f激动剂

Also Published As

Publication number Publication date
CA2271272A1 (en) 1998-05-22
ATE253063T1 (de) 2003-11-15
WO1998020875A1 (en) 1998-05-22
US5998622A (en) 1999-12-07
ES2210463T3 (es) 2004-07-01
US5817671A (en) 1998-10-06
AU5435298A (en) 1998-06-03
DE69725825D1 (de) 2003-12-04
DE69725825T2 (de) 2004-08-12
JP2001503774A (ja) 2001-03-21
ZA979961B (en) 1999-05-05
PT842934E (pt) 2004-03-31
EP0842934A1 (en) 1998-05-20
US5919936A (en) 1999-07-06
EP0842934B1 (en) 2003-10-29
NO991974L (no) 1999-04-26
ID18883A (id) 1998-05-20
IL129592A0 (en) 2000-02-29
DK0842934T3 (da) 2004-03-08
CO4910133A1 (es) 2000-04-24
NO991974D0 (no) 1999-04-26

Similar Documents

Publication Publication Date Title
PT842934E (pt) Agonistas de 5-ht1f
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
ATE168992T1 (de) 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline
PT618190E (pt) 9-¬glicil substituido)amido|-6-(substituido)-5-hidroxi-6-desoxitetraciclinas
DK1200418T3 (da) Nematodicide trifluorbutener
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
PT971922E (pt) Compostos de tetra-hidropirido
ID25478A (id) Agonis 5-ht1f
BR9902084A (pt) Heterociclos.
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose
PE61999A1 (es) Compuestos de tetrahidropiridina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed